FDA approves Eli Lilly obesity drug after trials show 22% average weight loss
The U.S. Food and Drug Administration has approved Eli Lilly’s new obesity treatment after late-stage clinical trials showed patients lost an average of 22% of their body weight. The decision marks a…
科学 6 回表示 9日前